Is metformin an appropriate therapy for melanoma, and what dosing and monitoring would be recommended if used off‑label?

Metformin is NOT an appropriate therapy for melanoma

Metformin should not be used as a treatment for melanoma outside of clinical trials. The most recent and authoritative guidelines from ASCO (2023) and NCCN (2024) make no mention of metformin in their comprehensive treatment algorithms for melanoma, despite extensive recommendations for established therapies 1, 2. These guidelines prioritize immune checkpoint inhibitors (nivolumab, pembrolizumab, ipilimumab), targeted therapies for BRAF-mutant disease (dabrafenib/trametinib, encorafenib/binimetinib), and oncolytic immunotherapy (talimogene laherparepvec) based on high-quality evidence demonstrating improvements in survival and quality of life.

Why Guidelines Don't Support Metformin

The absence of metformin from evidence-based melanoma treatment guidelines is telling. While preclinical and retrospective studies suggest potential mechanisms of action—including AMPK activation, autophagy inhibition, and enhanced immune checkpoint blockade—the clinical evidence remains insufficient and contradictory:

• A 2018 retrospective study showed no statistically significant improvement in objective response rate (68.2% vs 54.5%, P=0.31), disease control rate (77.3% vs 60.6%, P=0.19), overall survival, or progression-free survival when metformin was combined with immune checkpoint inhibitors 3
• A 2023 Swedish cohort study found improved overall survival in diabetic melanoma patients taking metformin (HR 0.68), but no improvement in melanoma-specific survival, suggesting the benefit may relate to diabetes management rather than direct anti-tumor effects 4
• A 2026 review concluded that while mechanistic data are "biologically plausible," clinical results remain "variable" and "inconsistent" 5

The Evidence Hierarchy Problem

Guideline-level evidence trumps preclinical research. The studies supporting metformin consist primarily of:

• In vitro cell culture experiments 6, 7, 8, 9, 10
• Retrospective observational data in diabetic populations 4
• One small retrospective cohort (n=55) showing non-significant trends 3

None of these meet the threshold for changing practice in a disease where we have proven, FDA-approved therapies with strong survival benefits. The ASCO guidelines are explicit: for BRAF wild-type metastatic melanoma, first-line therapy should be nivolumab plus ipilimumab, nivolumab plus relatlimab, nivolumab alone, or pembrolizumab—all with high-quality evidence and strong recommendations 1.

Clinical Implications

If a patient or provider asks about metformin for melanoma:

For patients WITH diabetes and melanoma:

• Continue metformin for diabetes management per standard dosing (500-2550 mg/day in divided doses) 11
• The potential survival benefit seen in retrospective studies may be real but is likely related to metabolic control, not direct anti-melanoma activity
• Do not substitute metformin for guideline-recommended melanoma therapies

For patients WITHOUT diabetes:

• Do not initiate metformin off-label for melanoma treatment
• Metformin's FDA-approved indication is type 2 diabetes mellitus only 11
• Off-label use would expose patients to potential adverse effects (lactic acidosis risk, GI intolerance) without proven benefit
• Refer to clinical trials if interested in metabolic approaches

Monitoring Considerations (If Used Off-Label Despite Recommendations)

Should a provider proceed with off-label metformin despite lack of evidence—which I strongly advise against—the FDA label mandates 11:

• Assess eGFR before initiation (contraindicated if <30 mL/min/1.73m²)
• Do not initiate if eGFR 30-45 mL/min/1.73m²
• Monitor renal function periodically
• Discontinue before iodinated contrast procedures in at-risk patients
• Standard dosing would be 500 mg twice daily, titrated to 2000-2550 mg/day

However, no melanoma-specific dosing or monitoring protocols exist because metformin is not an established melanoma therapy.

Common Pitfalls

• Delaying proven therapy: The greatest risk is that patients might delay or refuse immune checkpoint inhibitors or targeted therapy in favor of metformin, which has no proven efficacy for melanoma-specific survival
• Misinterpreting retrospective data: Improved overall survival in diabetic patients does not equal anti-melanoma efficacy
• Overvaluing preclinical data: Mechanistic studies showing effects on cancer stem cells or autophagy do not translate to clinical benefit without prospective trials

The Bottom Line

Metformin remains an investigational agent for melanoma. The 2026 review appropriately concludes that "further prospective and controlled studies are needed" 5. Until such trials demonstrate survival benefit, metformin has no role in melanoma treatment outside of clinical trials. Patients should receive guideline-concordant therapy with immune checkpoint inhibitors or targeted agents, which have transformed melanoma from a uniformly fatal disease to one with meaningful long-term survival rates.